The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study

Contraception

Volumn 75, Issue 3, 2007, Pages 199-203

  Fruzzetti, Franca ^a   Lello, Stefano ^b   Lazzarini, Veronica ^a   Fratta, Stefania ^b   Orrù, Marisa ^b   Sorge, Roberto ^c   Minerba, Luigi ^b   Ricci, Cabiria ^a   Genazzani, Andrea Riccardo ^a   Melis, Gian Benedetto ^b   Paoletti, Anna Maria ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Body composition; Drospirenone; Extracellular water; Menstrual cycle; Multifrequency bioelectrical impedance; Oral contraceptives; Total body water

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ELECTROLYTE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; ELECTROLYTE BLOOD LEVEL; EXTRACELLULAR FLUID; FAT BODY; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; IMPEDANCE; INTRACELLULAR FLUID; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; TOTAL BODY WATER; WAIST HIP RATIO;

ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BODY COMPOSITION; BODY WATER; BODY WEIGHT; CONTRACEPTIVES, ORAL, COMBINED; ELECTRIC IMPEDANCE; ESTROGENS; ETHINYL ESTRADIOL; EXTRACELLULAR FLUID; FEMALE; HUMANS; INTRACELLULAR FLUID; LUTEAL PHASE; MINERALOCORTICOIDS;

EID: 33846840621     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.10.011     Document Type: Article

References (22)

1. Rosenberg M.J., and Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 179 (1998) 577-582
2. Walters W.A.W., and Lim Y.L. Haemodynamic changes in women taking oral contraceptives. J Obstet Gynaecol Br Commonw 77 (1970) 1088-1099
3. Crane M.G., and Harris J.J. Effect of oestrogens and gestagens on exchangeable sodium. In: Fregly M.J., and Fregly M.S. (Eds). Oral contraceptives and high blood pressure (1974), Dolphin Press, Gainesvill (FL) 159-169
4. Oelkers W.K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61 (1996) 166-171
5. Oelkers W.K., Helmerhorst F.M., Wuttke W., and Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 14 (2000) 204-213
6. Oelkers W., Berger V., Bolik A., et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 73 (1991) 837-842
7. Stachenfeld N.S., DiPietro L., Kokoszka C.A., Silca C., Keef D.L., and Nadel E.R. Physiological variability of fluid-regulation hormones in young women. J Appl Physiol 86 (1999) 1092-1096
8. Elger W., Beier S., Pollow K., et al. Conception and pharmacological profile of drospirenone. Steroids 68 (2003) 891-905
9. Elger W., Steinbeck H., Schillinger E., et al. Endocrine pharmacological profile of gestodene. In: Elstein E. (Ed). Gestodene. Development of a new gestodene-containing low dose oral contraceptive (1987), Parthenon Publishing, Carnforth (UK) 19-33
10. Oddens B.J. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 59 (1999) 277-286
11. Philibert D., Bouchoux F., Degryse M., et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 13 (1999) 316-326
12. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
13. Foidart J.M. Added benefits of drospirenone for compliance. Climacteric 8 Suppl 3 (2005) 28-34
14. Apter D., Borsos A., Baumgartner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
15. Mansour D. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 7 Suppl 3 (2002) 35-41
16. Kyle U.G., Bosaeus I., De Lorenzo A.D., et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr 23 (2004) 1430-1453
17. Martinoli R., Mohamed E.I., Maiolo C., et al. Total body water estimation using bioelectrical impedance: a meta-analysis of the data available in the literature. Acta Diabetol 40 Suppl 1 (2003) S203-S206
18. Gudivaka R., Schoeller D.A., Kushner R.F., and Bolt M.J. Single and multifrequency model for bioelectrical impedance analysis of body water compartments. J Appl Physiol 87 (1999) 1087-1096
19. Stachenfeld N.S., Silva C., Keef D.L., Kokoszka C.A., and Nadel E.R. Effects of oral contraceptives on body fluid regulation. J Appl Physiol 87 (1999) 1016-1025
20. Reubinoff B.E., Grubstein A., Meirow D., Berry E., Schenker J.G., and Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 63 (1995) 516-521
21. de Melo N.R., Aldrighi J.M., Faggion Jr. D., et al. A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet (gestodene75/EE20) on body fat. Contraception 70 (2004) 65-71
22. Machado R.B., Tachotti F., Cavenague G., and Maia E. Effects of two different oral contraceptives on total body water: a randomized study. Contraception 73 (2006) 344-347